Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05286242 · ClinicalTrials.gov registry record
Evaluating the Immune Response to COVID19 Vaccination in Immunodeficient Patients
A clinical trial of Multiple Sclerosis and Autoimmune Blistering Disease, sponsored by Yale University.
- Active
- Registry status
- 400
- Enrollment target
- 1
- Study location
NCT05286242 is a study of Multiple Sclerosis and Autoimmune Blistering Disease that is active but no longer recruiting, run by Yale University. The registered enrollment target is 400 participants, below the 584-participant average among 315 other Multiple Sclerosis trials with a reported enrollment target (32% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05286242, a study of Multiple Sclerosis and Autoimmune Blistering Disease, is active but no longer recruiting, sponsored by Yale University.
- ACTIVE NOT RECRUITING
- Registry status
- 400 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to understand the immune response to coronavirus disease-19 (COVID-19) vaccination in patients on B-cell depleting therapies (BCDT) over time, which in the future may help to inform clinical decision making in this patient population.
Conditions Studied
Interventions
- BIOLOGICAL COVID19 vaccine
Study Locations (1)
Connecticut
- Yale University - New Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 400 participants |
| Start Date | 2021-02-10 |
| Est. Completion | 2026-06-30 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05286242
The ClinicalTrials.gov registry entry for NCT05286242 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 400 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 584-participant average among 315 other Multiple Sclerosis trials with a reported enrollment target (32% lower). The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Multiple Sclerosis appearing as the primary indexed condition, and to 1 intervention - of which COVID19 vaccine is the first listed.
NCT05286242 reports 1 study location spanning 1 distinct geographic area - top geographies include Connecticut.
Frequently Asked Questions
What is clinical trial NCT05286242 about?
NCT05286242 is a clinical study titled "Evaluating the Immune Response to COVID19 Vaccination in Immunodeficient Patients". The purpose of this study is to understand the immune response to coronavirus disease-19 (COVID-19) vaccination in patients on B-cell depleting therapies (BCDT) over time, which in the future may help to inform clinical decision making in this patient population.
What is the current status of trial NCT05286242?
This trial is currently active not recruiting. The enrollment target is 400 participants. The study started on 2021-02-10. Estimated completion is 2026-06-30.
What conditions does trial NCT05286242 study?
This clinical trial studies the following conditions: Multiple Sclerosis, Autoimmune Blistering Disease, B-Cell Deficiency.
What interventions are being tested in trial NCT05286242?
The interventions under investigation include: COVID19 vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT05286242?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05286242 being conducted?
This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Sclerosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Assessment of Neuroinflammation in Central Inflammatory Disorders Using [F-18]DPA-714.
RECRUITING · Phase 1
-
Prepare the Mind: Can Coaching in Goal-directed Behaviour Increase the Success of Cognitive Rehabilitation in People With MS?
RECRUITING · NA
-
Incremental Vestibulo-ocular Reflex Adaptation as a Novel Treatment for Dizziness in People With Multiple Sclerosis
RECRUITING · NA
-
Vancomycin Study in Multiple Sclerosis (MS)
RECRUITING · Phase 1
-
IConquerMS™ - a Patient-Powered Research Network for Multiple Sclerosis
RECRUITING
-
Prospective Investigation of Multiple Sclerosis in the Three Rivers Region
RECRUITING
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.